Filing Details
- Accession Number:
- 0000899243-16-034882
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-12-02 21:40:25
- Reporting Period:
- 2016-11-30
- Filing Date:
- 2016-12-02
- Accepted Time:
- 2016-12-02 21:40:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1285819 | Omeros Corp | OMER | Pharmaceutical Preparations (2834) | 911663741 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1472160 | Md A Gregory Demopulos | 201 Elliott Avenue West Seattle WA 98119 | Chairman, Ceo & President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-11-30 | 97,559 | $0.98 | 1,801,381 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-11-30 | 97,559 | $12.21 | 1,703,822 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-12-01 | 106,521 | $0.98 | 1,810,343 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-12-01 | 105,522 | $11.56 | 1,704,821 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2016-12-01 | 999 | $12.32 | 1,703,822 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-12-02 | 102,040 | $0.98 | 1,805,862 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-12-02 | 102,040 | $11.00 | 1,703,822 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-12-02 | 181,163 | $0.98 | 1,884,985 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-11-30 | 97,559 | $0.00 | 97,559 | $0.98 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-12-01 | 106,521 | $0.00 | 106,521 | $0.98 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-12-02 | 102,040 | $0.00 | 102,040 | $0.98 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-12-02 | 181,163 | $0.00 | 181,163 | $0.98 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 514,685 | 2016-12-11 | No | 4 | M | Direct | |
| 408,164 | 2016-12-11 | No | 4 | M | Direct | |
| 306,124 | 2016-12-11 | No | 4 | M | Direct | |
| 0 | 2016-12-11 | No | 4 | M | Direct |
Footnotes
- Open market sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person that provides for the exercise and sale of options to purchase 612,244 shares of common stock that expire on December 11, 2016 and 100 shares of common stock that expire on April 7, 2020; the latter at a threshold price of $100.00 per share. Under the plan, the options expiring on December 11, 2016, which do not provide for an extension of the exercise period, would be exercised and sold during fixed sale periods at specified prices and numbers in each sale period. Consistent with the applicable trading rules, the reporting person has had no further control over the terms or timing of sales under the plan. A portion of the proceeds from the exercise of the options expiring on December 11, 2016, all of which are non-qualified, are being used in part to fund the reporting person's exercise of all incentive stock options that otherwise would expire on December 11, 2016. See note (7) below.
- This transaction was executed in multiple trades at prices ranging from $12.06 to $12.59; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- This transaction was executed in multiple trades at prices ranging from $11.27 to $12.26; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- This transaction was executed in multiple trades at prices ranging from $12.27 to $12.37; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- This transaction was executed in multiple trades at prices ranging from $10.84 to $11.30; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- The option vested and became exercisable in 48 equal monthly installments. The first installment became exercisable on March 28, 2005 and subsequent installments became exercisable on each monthly anniversary thereafter.
- On December 2, 2016, the reporting person exercised incentive stock options to purchase 181,163 shares of common stock, which are being retained by the reporting person.
Billionaire Hedge Funds
